Clorox reported adjusted earnings per share of $1.66 for the quarter ending June 30, marking a 42% decline from the previous year. This substantial drop raises concerns for investors as the company faces challenges in organic sales and market volatility.

Key Highlights

  • Clorox Co. (NYSE: CLX) reported adjusted earnings per share of $1.66 for the fourth quarter ending June 30, 2026, down 42% from $2.87 in the same period last year.
  • Clorox faced a decrease in net sales primarily due to a 13% decline in organic sales.
  • The GOJO acquisition is a significant strategic step for Clorox, enhancing its portfolio in health and hygiene.

Clorox Co. (NYSE: CLX) reported adjusted earnings per share of $1.66 for the fourth quarter ending June 30, 2026, down 42% from $2.87 in the same period last year. This performance slightly missed Wall Street's consensus estimate of $1.67. The company experienced a 2% decline in net sales, totaling $1.95 billion.

Comparatively, shares of Clorox are down 2.6% year-to-date, indicating broader market concerns. Despite the decline, Clorox's recent acquisition of GOJO Industries, which contributed significantly to revenues, adds complexity to this picture.

Q4 Performance Analysis

Clorox faced a decrease in net sales primarily due to a 13% decline in organic sales. The impact of the ERP transition accounted for approximately 13.5 points in this adjustment. The company noted that while the acquisition of GOJO added almost 10 points to overall net sales, it wasn't enough to offset the organic downturn.

Meanwhile, gross margin fell to 41.3%, down 520 basis points year-over-year, driven by higher commodity costs and integration costs associated with GOJO. These results underline the challenges Clorox faces in stabilizing profitability amid operational transitions, and such declines in earnings can make investors wary.

Strategic Developments

The GOJO acquisition is a significant strategic step for Clorox, enhancing its portfolio in health and hygiene. Following this merger, the Health and Wellness segment saw a 16% increase in net sales, benefitting from 10 points of higher volume. Although overall performance suffered, the acquisition is expected to unlock synergies that help the company adapt to changes in consumer behavior driven by ongoing health concerns.

Clorox has also nearly doubled its innovation investments, aiming to launch new products that meet evolving consumer demands. These measures could bolster its long-term growth trajectory, yet immediate concerns remain in light of current financial metrics.

Market Dynamics & Future Outlook

Despite a challenging environment marked by consumer price sensitivity and ongoing cost volatility, Clorox's stock has shown some resilience, gaining 1.9% over the past month. Analysts have their eyes on how effectively the company can manage its operational complexities and leverage GOJO acquisition for future growth. As of now, Clorox enters fiscal year 2027 with a vigilant outlook, expecting a continued focus on innovation and strategic growth, even as it navigates a volatile market backdrop.

Investors will look for further clarity during the next earnings call regarding the effectiveness of its strategies implemented in this quarter.

Peers Moving on This News

  • Procter & Gamble Co (PG) little changed
  • Colgate-Palmolive Co (CL) little changed
  • Kimberly-Clark Corp (KMB) up 0.4%

Analysis based on the Form 8-K filed 3 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.